MULti-Tumour based prediction and manipulation of Immune Response

Información del proyecto

MULTIR

Identificador del acuerdo de subvención: 101136926

DOI

10.3030/101136926

Fecha de la firma de la CE 7 Diciembre 2023

Fecha de inicio 1 Enero 2024

Fecha de finalización 31 Diciembre 2027

Financiado con arreglo a

• Health

Coste total

€ 8 547 711,50

Aportación de la UE

€ 8 547 711,50

Coordinado por

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Documents, reports (3)

Policy brief formulating recommendations based on the research and innovation strand of the “Understanding (tumour-host interactions)”annual cluster meeting
Dissemination plan

Dissemination plan defined (updated M24)

Stakeholder engagement plan

Multi-stakeholder engagement plan defined

Websites, patent fillings, videos etc. (2)

Common video and brochure for the “Understanding (tumour-host interactions)” cluster

A common video and a brochure for the “ Understanding (tumour-host interactions)” cluster will be produced in collaboration with the other projects of the cluster

Launch of the website

Website open to the public

Publicaciones

Conference proceedings (3)

Abstract 2190: Genomic scarring score is associated with T cell exhaustion in early stage non small cell lung cancer

Autores: Ioannis Pateras, Konstantinos Ntostoglou, Georgios Christodoulopoulos, Katerina Tsilingiri, Anna Chalari, Giannis Vatsellas, Georgia Christopoulou, Pantelis Constantoulakis, Eleni Patsea, Konstantinos Potaris, Ioannis Vamvakaris, Dora Chatzidaki, Georgina Zachou, Athanasios Kotsakis, Apostolos Klinakis, Vassilis Georgoulias
Publicado en: Cancer Research, Edición 85, 2025, ISSN 0008-5472
Editor: American Association for Cancer Research (AACR)
DOI: 10.1158/1538-7445.AM2025-2190

1233P Genomic scarring score as a criterion for PARP inhibitor administration in early-stage NSCLC

Autores: A. Klinakis, K. Tsilingiri, A. Chalari, A. Voutsina, G. Christopoulou, G. Vatselas, K. Potaris, I. Vamvakaris, D. Hatzidaki, G. Zachou, V. Georgoulias, P. Konstantoulakis, A. Kotsakis
Publicado en: Annals of Oncology, Edición 35, 2024, ISSN 0923-7534
Editor: Elsevier BV
DOI: 10.1016/J.ANNONC.2024.08.1292

Abstract 2919: Homologous recombination deficiency in non-small cell lung cancer: genetic and epigenetic causes beyond HRR

Autores: Katerina Tsilingiri, Anna Chalari, Georgia Christopoulou, Alexandra Voutsina, Pantelis Constantoulakis, Konstantinos Potaris, Ioannis Vamvakaris, Dora Hatzidaki, Georgina Zachou, Giannis Vatsellas, Vassilis Georgoulias, Athanasios Kotsakis, Apostolos Klinakis
Publicado en: Cancer Research, Edición 85, 2025, ISSN 0008-5472
Editor: American Association for Cancer Research (AACR)
DOI: 10.1158/1538-7445.AM2025-2919

Peer reviewed articles (4)

Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells

Autores: Thomas Sevrin, Hiroaki Imoto, Sarah Robertson, Nora Rauch, Uscinnia Dyn’ko, Katerina Koubova, Kieran Wynne, Walter Kolch, Oleksii S. Rukhlenko, Boris N. Kholodenko
Publicado en: Cell Reports, Edición 43, 2024, ISSN 2211-1247
Editor: Elsevier BV
DOI: 10.1016/J.CELREP.2024.114710

Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer

Autores: Katerina Tsilingiri, Anna Chalari, Georgia Christopoulou, Alexandra Voutsina, Pantelis Constantoulakis, Κonstantinos Potaris, Ioannis Vamvakaris, Dora Hatzidaki, Georgina Zachou, Giannis Vatsellas, Vassilis Georgoulias, Athanasios Kotsakis, Apostolos Klinakis
Publicado en: npj Precision Oncology, Edición 8, 2024, ISSN 2397-768X
Editor: Springer Science and Business Media LLC
DOI: 10.1038/S41698-024-00777-6

Cell State Transition Models Stratify Breast Cancer Cell Phenotypes and Reveal New Therapeutic Targets

Autores: Oleksii S. Rukhlenko, Hiroaki Imoto, Ayush Tambde, Amy McGillycuddy, Philipp Junk, Anna Tuliakova, Walter Kolch, Boris N. Kholodenko
Publicado en: Cancers, Edición 16, 2025, ISSN 2072-6694
Editor: MDPI AG
DOI: 10.3390/CANCERS16132354

cSTAR analysis identifies endothelial cell cycle as a key regulator of flow-dependent artery remodeling

Autores: Hanqiang Deng, Oleksii S. Rukhlenko, Divyesh Joshi, Xiaoyue Hu, Philipp Junk, Anna Tuliakova, Boris N. Kholodenko, Martin A. Schwartz
Publicado en: Science Advances, Edición 11, 2025, ISSN 2375-2548
Editor: American Association for the Advancement of Science (AAAS)
DOI: 10.1126/SCIADV.ADO9970